Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory minute volume

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Respiratory minute volume. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-005624-26 Sponsor Protocol Number: 03-CL-1401 Start Date*: 2016-05-30
    Sponsor Name:Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.)
    Full Title: A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA.
    Medical condition: Respiratory Distress Syndrome (RDS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021735 Infant respiratory distress syndrome LLT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038690 Respiratory distress syndrome (neonatal) LLT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10028974 Neonatal respiratory distress syndrome PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007775-17 Sponsor Protocol Number: ALMED-07-C2-017 Start Date*: 2009-10-14
    Sponsor Name:Air Liquide
    Full Title: A single centre, exploratory, phase II, cross-over, randomised trial, evaluating the effect of spontaneously breathing Helium/Oxygen (65%/35%), to either spontaneously breating Nitrogen/Oxygen (65%...
    Medical condition: Severe chronic obstructive pneumonary disease (COPD) patients during a Six-Minute Walking Test
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003595-36 Sponsor Protocol Number: ERN_11-0670 Start Date*: 2012-04-26
    Sponsor Name:University of Birmingham
    Full Title: Can muscle dysfunction in COPD be altered by oxygenation in patients with intermittent hypoxia on exertion?
    Medical condition: Chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000253-21 Sponsor Protocol Number: CLA-CC10-02 Start Date*: Information not available in EudraCT
    Sponsor Name:Therabron Therapeutics Inc.
    Full Title: Efficacy of recombinant human club (clara) cell 10kDa protein (CC10) administered to premature neonates with respiratory distress syndrome.
    Medical condition: Bronchopulmonary Dysplasia (BPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003415-29 Sponsor Protocol Number: 2.0 Start Date*: 2023-04-03
    Sponsor Name:Leiden University Medical Centre
    Full Title: The effect of antenatal acetaminophen administration on breathing effort of premature infants at birth: a pilot study
    Medical condition: Pregnant women expected to deliver between 24 and 30 weeks' gestation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001744-11 Sponsor Protocol Number: PT003019-01 Start Date*: 2016-10-31
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005059-35 Sponsor Protocol Number: TMP-2204-2021-47 Start Date*: 2022-01-25
    Sponsor Name:F4-Pharma GmbH i.G.
    Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    24.0 10038738 - Respiratory, thoracic and mediastinal disorders 10085269 ARDS disease progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004152-19 Sponsor Protocol Number: ELASTIC2011 Start Date*: 2012-04-18
    Sponsor Name:Ludwig Boltzmann institute for COPD and Respiratory Epidemiology
    Full Title: Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001834-20 Sponsor Protocol Number: APHP191105 Start Date*: 2021-12-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary sarcoidosis
    Medical condition: mediastino-pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000344-21 Sponsor Protocol Number: MP1032-CT05 Start Date*: 2021-07-21
    Sponsor Name:MetrioPharm AG
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD...
    Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-004782-24 Sponsor Protocol Number: PRM-151-202 Start Date*: 2016-03-01
    Sponsor Name:Promedior, Inc.
    Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000137-31 Sponsor Protocol Number: 2017-2019 Start Date*: 2017-12-19
    Sponsor Name:VU University Medical Center
    Full Title: Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037454 Pulmonary vascular disorders HLGT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001262-15 Sponsor Protocol Number: BiPhox-Trial Start Date*: 2020-03-02
    Sponsor Name:Medical University Innsbruck
    Full Title: Comparison of Biphozyl® and Phoxilium® as a replacement fluid during Continuous Veno-Venous Hemofiltration (CVVH) with Regional Citrate Anticoagulation (RCA) for Acute Kidney Injury (AKI) in adults...
    Medical condition: Acute Kidney Injury (AKI). This is a A prospective, randomized, controlled, open, cross-over, Phase II, single-center pilot study to assess the effects of two different continuous veno-venous hemof...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001172-12 Sponsor Protocol Number: CQMF149F2202 Start Date*: 2012-09-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, 12-week treatment, parallelgroup study to evaluate the efficacy and safety of QMF149 (150 μg/160 μg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 μ...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed) BG (Completed) BE (Completed) SE (Completed) FI (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003561-16 Sponsor Protocol Number: TAK-242/01-04-TL-242-011 Start Date*: 2005-12-21
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis
    Medical condition: Severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8 10040047 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006173-33 Sponsor Protocol Number: ALMED-07-C3-009 Start Date*: 2009-10-09
    Sponsor Name:Air Liquide
    Full Title: An international phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneo...
    Medical condition: Patients eligible for this study are critically ill patients with COPD admitted in ICU for an exacerbation of their chronic disease with hypercapnic acute respiratory failure.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended) DE (Completed) IT (Ongoing) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-004193-39 Sponsor Protocol Number: TAK-665-4001 Start Date*: 2024-12-04
    Sponsor Name:Takeda Biopharmaceuticals India Pvt. Ltd.
    Full Title: A Prospective, Multicenter, Single-arm, Open-label, Interventional Phase IV Study to Evaluate the Safety and Efficacy of Idursulfase (r-DNA Origin) (Elaprase™) in Indian Pediatric and Adult Populat...
    Medical condition: Hunter syndrome (Mucopolysaccharidosis II, [MPS II])
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002114-40 Sponsor Protocol Number: APHP200527 Start Date*: 2020-07-30
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Nintedanib for the treatment of SARS-Cov-2 induced pulmonary fibrosis
    Medical condition: Patients 2 to 6 months after Covid-19 acute pneumonia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002509-22 Sponsor Protocol Number: ID2687 Start Date*: 2019-11-21
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Impact of totally transdermal sedation in the weaning from remifentanil infusion among critically ill patients undergoing mechanical ventilation: a pilot randomized-controlled Study
    Medical condition: Invasive mechanical ventilation is a lifesaving intervention among critically ill patients. However, prolonged ventilation is associated with increased morbidity and mortality. Optimal processes fo...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003921-13 Sponsor Protocol Number: 12/0368 Start Date*: 2013-06-07
    Sponsor Name:University College London
    Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE).
    Medical condition: Pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 04:48:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA